Comparative Pharmacology
Head-to-head clinical analysis: TESTOSTERONE ENANTHATE versus TESULOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTOSTERONE ENANTHATE versus TESULOID.
TESTOSTERONE ENANTHATE vs TESULOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone enanthate is a prodrug of testosterone, which binds to and activates androgen receptors (AR), modulating gene expression and exerting anabolic and androgenic effects. It also exhibits some affinity for estrogen receptors via aromatization.
Tesuloid is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), thereby reducing pro-inflammatory cytokine production and immune-mediated inflammation.
50-400 mg intramuscularly every 2-4 weeks
Intravenous infusion of 500 mg over 60 minutes every 2 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 4-5 days (range 3.5-7 days) after intramuscular injection due to slow absorption from the oily depot; supports weekly to biweekly dosing intervals.
16–20 hours in healthy adults; prolonged to 30–40 hours in moderate renal impairment (CrCl <50 mL/min); clinically significant accumulation risk in renal disease.
Primarily renal (90% as glucuronide and sulfate conjugates, 6% unchanged) and biliary/fecal (10%).
Primarily renal excretion (85% unchanged, 10% as glucuronide conjugate); 5% fecal.
Category D/X
Category C
Androgen
Androgen